Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 25 of 214 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/30/15
End: 08/08/22
Due: 08/08/23
Phase: N/A
Priority: Normal
Start: 01/31/06
End: 03/31/08
Due: 03/31/09
Phase: N/A
Priority: Normal
Start: 12/31/03
End: 04/30/07
Due: 04/30/08
Phase: N/A
Priority: Normal
Start: 11/30/03
End: 01/31/08
Due: 01/31/09
Phase: N/A
Priority: Normal
Start: 01/24/19
End: 01/31/31
Due: 01/31/32
Phase: N/A
Priority: Normal
Start: 10/31/08
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 09/30/98
End: 07/31/03
Due: 07/31/04
Phase: N/A
Priority: Normal
Start: 06/30/14
End: 10/31/17
Due: 10/31/18
Phase: N/A
Priority: Normal
Start: 10/03/23
End: 12/31/28
Due: 12/31/29
Phase: N/A
Priority: Normal
Start: 05/22/20
End: 07/31/25
Due: 07/31/26
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 11/30/10
Due: 11/30/11
Phase: N/A
Priority: Normal
Start: 05/31/08
End: 03/31/09
Due: 03/31/10
Phase: N/A
Priority: Normal
Start: 07/08/19
End: 07/14/24
Due: 07/14/25
Phase: N/A
Priority: Normal
Start: 06/30/08
End: 05/31/09
Due: 05/31/10
Phase: N/A
Priority: Normal
Start: 08/07/19
End: 06/30/20
Due: 06/30/21
Phase: N/A
Priority: Normal
Start: 11/30/09
End: 10/31/16
Due: 10/31/17
Phase: N/A
Priority: Normal
Start: 05/17/23
End: 05/31/29
Due: 05/31/30
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Phase: N/A
Priority: Normal
Start: 11/30/16
End: 10/31/23
Due: 10/31/24
Phase: N/A
Priority: Normal
Start: 05/31/08
End: 12/31/10
Due: 12/31/11
Phase: N/A
Priority: Normal
Start: 08/31/07
End: 02/28/11
Due: 02/28/12
Phase: N/A
Priority: Normal
Start: 10/28/19
End: 10/06/20
Due: 10/06/21
Phase: N/A
Priority: Normal
Start: 03/03/17
End: 08/03/21
Due: 08/03/22
Phase: N/A
Priority: Normal
Start: 09/05/18
End: 07/13/20
Due: 07/13/21
Phase: N/A
Priority: Normal
Start: 03/13/20
End: 03/03/23
Due: 03/03/24
Phase: N/A
Priority: Normal
Start: 08/07/17
End: 11/27/23
Due: 11/27/24